Recombinant
RabMAb

Recombinant Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312)

Overview

  • Product name

    Anti-BCRP/ABCG2 antibody [EPR2099(2)]
    See all BCRP/ABCG2 primary antibodies
  • Description

    Rabbit monoclonal [EPR2099(2)] to BCRP/ABCG2
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC,IHC-P or IP
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human BCRP/ABCG2 aa 150-250 (intracellular). The exact sequence is proprietary.

  • Positive control

    • Human fetal liver, JAR, 293T, HepG2, and Human placenta lysates.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab108312 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 72 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC,IHC-P or IP.
  • Target

    • Function

      Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP-dependent increase in the efflux of rhodamine 123.
    • Tissue specificity

      Highly expressed in placenta. Low expression in small intestine, liver and colon.
    • Sequence similarities

      Belongs to the ABC transporter superfamily. ABCG family. Eye pigment precursor importer (TC 3.A.1.204) subfamily.
      Contains 1 ABC transmembrane type-2 domain.
      Contains 1 ABC transporter domain.
    • Post-translational
      modifications

      Glycosylation-deficient ABCG2 is normally expressed and functional.
    • Cellular localization

      Cell membrane.
    • Information by UniProt
    • Database links

    • Alternative names

      • ABC transporter antibody
      • ABC15 antibody
      • ABCG 2 antibody
      • ABCG2 antibody
      • ABCG2_HUMAN antibody
      • ABCP antibody
      • ATP binding cassette sub family G (WHITE) member 2 antibody
      • ATP binding cassette transporter G2 antibody
      • ATP-binding cassette sub-family G member 2 antibody
      • BCRP antibody
      • BCRP1 antibody
      • BMDP antibody
      • Breast cancer resistance protein antibody
      • CD338 antibody
      • CDw338 antibody
      • CDw338 antigen antibody
      • EST157481 antibody
      • GOUT1 antibody
      • MGC102821 antibody
      • Mitoxantrone resistance associated protein antibody
      • Mitoxantrone resistance-associated protein antibody
      • MRX antibody
      • Multi drug resistance efflux transport ATP binding cassette sub family G (WHITE) member 2 antibody
      • MXR antibody
      • MXR1 antibody
      • Placenta specific ATP binding cassette transporter antibody
      • Placenta specific MDR protein antibody
      • Placenta-specific ATP-binding cassette transporter antibody
      • UAQTL1 antibody
      see all

    Images

    • All lanes : Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312) at 1/1000 dilution

      Lane 1 : Human fetal liver lysate
      Lane 2 : JAR lysate
      Lane 3 : 293T lysate
      Lane 4 : HepG2 lysate
      Lane 5 : Human placenta lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 72 kDa

    References

    This product has been referenced in:

    • Ding Y  et al. Levistolide A synergistically enhances doxorubicin-induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway. Oncol Rep 41:1198-1208 (2019). Read more (PubMed: 30483812) »
    • Wang X  et al. Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis. EBioMedicine 40:251-262 (2019). Read more (PubMed: 30738829) »
    See all 9 Publications for this product

    Customer reviews and Q&As

    1-3 of 3 Abreviews or Q&A

    Application
    Immunohistochemistry (Frozen sections)
    Sample
    Human Tissue sections (human liver)
    Permeabilization
    No
    Specification
    human liver
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 20°C
    Fixative
    methanol:acetone (1:1 ratio)

    Abcam user community

    Verified customer

    Submitted Oct 30 2015

    Application
    Immunocytochemistry/ Immunofluorescence
    Sample
    Human Cell (ES-derived hepatocytes)
    Permeabilization
    Yes - BSA diluted in PBS/0.1% Tween
    Specification
    ES-derived hepatocytes
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 20°C
    Fixative
    Methanol

    Abcam user community

    Verified customer

    Submitted Dec 12 2013

    Answer

    Thank you for contacting us.

    For ab108312, you could use human fetal liver (ab29890), JAR, 293T (ab95494), HepG2 (ab7900) or human placenta (ab29745) lysates as a positive control.

    For ab32574, you could consider using MRP-1 transfected HEK293 cell lysate as positive control.


    I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up